Rating Change
Needham reiterated its Buy rating on Recursion Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:RXRX) on October 19, 2026.
reiterateNASDAQ:RXRX
Needham Reiterates Buy Rating on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX)
Needham reiterated its Buy rating on Recursion Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:RXRX) on October 19, 2026.
At publication ·
What changed
Recursion Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:RXRX) · reiterate
- Firm
- Needham
- Rating
- Buy to Buy
- Price at event
- $3.65
- Market capitalization
- $1.8B
At a glance
Key takeaways
- Needham reiterated a Buy rating on Recursion Pharmaceuticals (RXRX) on October 19, 2026, with the stock trading at $3.65 and a market cap of $1.8 billion.
Market Context
Recursion Pharmaceuticals, Inc. Class A Common Stock operates in the Healthcare sector. The stock currently trades at $3.65 with a market capitalization of $1.8B. The stock has declined 49.0% over the past 52 weeks.
Analyst coverage from Needham provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Recursion Pharmaceuticals, Inc. Class A Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Recursion Pharmaceuticals, Inc. Class A Common Stock
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 19, 2026 | Needham | Buy | N/A |
| May 14, 2026 | Morgan Stanley | Equal-Weight | N/A |
| May 07, 2026 | Needham | Buy | N/A |
| Apr 30, 2026 | JP Morgan | Overweight | N/A |
| Feb 26, 2026 | B of A Securities | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View RXRX Stock Page
Frequently Asked Questions
What does the Buy rating mean for RXRX?
A rating of Buy from Needham reflects the analyst's outlook on Recursion Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:RXRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RXRX forecast page.